Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Amortization of Deferred Charges (2016 - 2017)

Historic Amortization of Deferred Charges for Cardiff Oncology (CRDF) over the last 6 years, with Q2 2017 value amounting to -$70657.0.

  • Cardiff Oncology's Amortization of Deferred Charges fell 595.0% to -$70657.0 in Q2 2017 from the same period last year, while for Jun 2017 it was -$271124.0, marking a year-over-year decrease of 30654.98%. This contributed to the annual value of -$201037.0 for FY2016, which is N/A changed from last year.
  • As of Q2 2017, Cardiff Oncology's Amortization of Deferred Charges stood at -$70657.0, which was down 595.0% from -$66119.0 recorded in Q1 2017.
  • Cardiff Oncology's 5-year Amortization of Deferred Charges high stood at $2.3 million for Q1 2013, and its period low was -$70657.0 during Q2 2017.
  • For the 4-year period, Cardiff Oncology's Amortization of Deferred Charges averaged around $1.1 million, with its median value being $1.1 million (2013).
  • As far as peak fluctuations go, Cardiff Oncology's Amortization of Deferred Charges changed by 0.0% in 2013, and later tumbled by 595.0% in 2017.
  • Over the past 4 years, Cardiff Oncology's Amortization of Deferred Charges (Quarter) stood at $2.3 million in 2013, then changed by 0.0% to $2.3 million in 2014, then plummeted by 102.88% to -$67659.0 in 2016, then fell by 4.43% to -$70657.0 in 2017.
  • Its Amortization of Deferred Charges stands at -$70657.0 for Q2 2017, versus -$66119.0 for Q1 2017 and -$67659.0 for Q4 2016.